For research use only. Not for therapeutic Use.
Opicapone（Cat No.:I005491）is a third-generation, peripheral catechol-O-methyltransferase (COMT) inhibitor used to enhance the efficacy of levodopa therapy in Parkinson’s disease. By inhibiting COMT, Opicapone reduces the breakdown of levodopa, leading to increased dopamine levels in the brain. This action helps to improve motor symptoms and reduce “off” periods in patients with Parkinson’s. Its once-daily dosing and long-lasting inhibition of COMT make it a convenient and effective option for managing motor fluctuations, offering improved control and quality of life for patients.
| Catalog Number | I005491 |
| CAS Number | 923287-50-7 |
| Synonyms | 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol |
| Molecular Formula | C15H10Cl2N4O6 |
| Purity | 98% |
| Target | COMT |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | IC50:98 μM |
| IUPAC Name | 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol |
| InChI | InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3 |
| InChIKey | ASOADIZOVZTJSR-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-] |
| Reference | [1]. Bonifácio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52. [2]. Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165. |
